Description  Claims  Drawing  Cited references 

US2008166427A   [0014] 

A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors   [0013] 
Lapatinib for Advanced or Metastatic Breast Cancer   [0015] 
Clinical use of crizotinib for the treatment of non-small cell lung cancer   [0016] 
Remington's Pharmaceutical Sciences Handbook   [0034] 
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology   [0053] 
ALK inhibitors in the treatment of advanced NSCLC   [0053] 
Lapatinib plus capecitabine for HER2-positive advanced breast cancer   [0053] 
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab   [0053] 
Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer   [0053] 
Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy   [0053] 
Fasting enhances the response of glioma to chemo- and radiotherapy   [0053] 
Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin   [0053] 
Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy   [0053] 
Toxicity in chemotherapy--when less is more   [0053] 
Fasting and cancer treatment in humans: A case series report   [0053] 
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression   [0053] 
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors   [0053] 
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells   [0053] 
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications   [0053] 
Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression   [0054]